Keyphrases
Heart Failure
100%
Evidence-based
100%
Pharmacotherapy
100%
Angiotensin Receptor Blockers
100%
Prescribing Patterns
100%
Angiotensin-converting Enzyme Inhibitor (ACEi)
100%
Beta-blockers
85%
Recommended Dose
85%
Mineralocorticoid Receptor Antagonists
71%
Patients with Heart Failure
57%
Guideline-directed Medical Therapy
57%
Hazard Ratio
42%
Reduced Ejection Fraction
42%
Asia
28%
Body Mass Index
28%
Composite Outcome
28%
Clinical Trials
14%
Acute Decompensated Heart Failure
14%
All-cause Mortality
14%
Patient Outcomes
14%
Bayes
14%
Singapore
14%
Boston Scientific
14%
Comorbidity
14%
Life-threatening
14%
Biomedical Research
14%
Underutilization
14%
Drug Class
14%
Patient Management
14%
Follow-up Data
14%
Research Councils
14%
New York Heart Association Class
14%
Symptomatic Heart Failure
14%
Drug Dosing
14%
Life Expectancy
14%
Heart Failure Stages
14%
Echocardiography
14%
Ejection Fraction
14%
Regional Variation
14%
OCT1
14%
Medical Research Council
14%
Cause-specific
14%
Outpatient Clinic
14%
Therapeutic Class
14%
Valvular Heart Disease
14%
Left Ventricular Systolic Dysfunction
14%
Patient Recruitment
14%
European Society of Cardiology Guidelines
14%
Unable or Unwilling
14%
Indication Bias
14%
Interpretation Guidelines
14%
Up-titration
14%
Funded Research
14%
Admission to Hospital
14%
Medical Analysis
14%
Medicine and Dentistry
Cohort Analysis
100%
Drug Therapy
100%
Congestive Heart Failure
100%
Angiotensin Receptor Antagonist
87%
ACE Inhibitor
87%
Recommended Drug Dose
75%
Mineralocorticoid Antagonist
62%
Combination Therapy
50%
Ejection Fraction
50%
Hazard Ratio
37%
Body Mass Index
25%
Clinical Trial
12%
Low Drug Dose
12%
Outpatient
12%
Valvular Heart Disease
12%
New York Heart Association Class
12%
Cardiology
12%
Echocardiography
12%
Biomedical Research
12%
Life Expectancy
12%
Medical Research
12%
Mental Capacity
12%
Decompensated Heart Failure
12%
Left Ventricular Systolic Dysfunction
12%
Comorbidity
12%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacotherapy
100%
Cohort Study
100%
Congestive Heart Failure
100%
Angiotensin Receptor Antagonist
77%
Dipeptidyl Carboxypeptidase Inhibitor
77%
Mineralocorticoid Antagonist
55%
Combination Therapy
44%
Clinical Trial
11%
Drug Dose
11%
Patient Recruitment
11%
Life Expectancy
11%
Left Ventricular Systolic Dysfunction
11%
Valvular Heart Disease
11%
Comorbidity
11%